Viela Bio

Investors/Media

Press Releases

Press Releases

10.09.2019
Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG , M.D., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (“Viela”) and Mitsubishi Tanabe Pharma Corporation
10.07.2019
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GAITHERSBURG, Md. , Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the closing of its previously announced initial public offering of 9,085,000 shares of
10.02.2019
Viela Bio Announces Pricing of Initial Public Offering
GAITHERSBURG, Md. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. , a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock at a price to the
9.09.2019
Viela Bio Announces Data Presentations at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Data from the N-MOmentum trial have been selected for an oral plenary session presentation at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Gaithersburg, MD—September 9, 2019 – Viela Bio today announced that data from the N-MOmentum trial—the largest global,
9.06.2019
Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder
The Lancet publishes results from the pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder Gaithersburg, MD—September 6, 2019 –Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients
8.27.2019
Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder
U.S. FDA accepts for review Viela Bio's first BLA filing p> Gaithersburg, MD—August 27, 2019 –Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for inebilizumab, an investigational anti-CD19 monoclonal
8.19.2019
Viela Bio Announces Appointment of Chris Nolet to its Board of Directors
Chris Nolet is appointed to Viela Bio Board of Directors Gaithersburg, MD—August 19, 2019 – Viela Bio today announced the appointment of Chris Nolet to its Board of Directors. Mr. Nolet brings more than 38 years of financial leadership experience in the Life Sciences industry.
7.01.2019
Viela Bio Appoints Mitchell Chan as Chief Financial Officer
Gaithersburg, MD—July 1, 2019 – Viela Bio today announced the appointment of Mitchell Chan as Chief Financial Officer, effective July 1. In this role, he will be responsible for leading corporate financing, financial operations, treasury, investor relations, corporate communications and corporate
6.17.2019
Viela Bio Closes $75 Million Series B Financing
Funding to support regulatory filing and pre-commercial planning for lead product candidate, inebilizumab, and to advance development of additional clinical candidates targeting autoimmune and inflammatory diseases Financing led by HBM Healthcare Investments Gaithersburg, MD—June 17, 2019  – Viela
5.28.2019
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China
Partnership accelerates access to inebilizumab in China and supports the mission of both companies to bring transformative therapies to more patients around the world Viela Bio is eligible to receive an upfront collaboration fee and milestone payments of more than $220 million plus royalties on
Displaying 1 - 10 of 14

Shareholder Tools